SynthesisJournal of Crohn's & colitis2024
Work Productivity Impairment in Persons with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.
Synthesis in Journal of Crohn's & colitis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07237516 (Zymfentra), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
Who cites it
17 citing papers in PubMed.
- Trial
- Sick Leave in Patients with Inflammatory Bowel Disease Before and After Diagnosis: A Retrospective Matched Cohort Study in Germany.Epidemiologia (Basel, Switzerland) · 2026Article
- Validity of a Toilet Seat for Automated Classification of Stool Form Using Falling Stool Sensing.Internal medicine (Tokyo, Japan) · 2026Article
- Anxiety and depression in newly diagnosed patients with inflammatory bowel disease (the IBSEN III study) compared with the general population in Norway.Journal of Crohn's & colitis · 2026Article
- Persistent disease burden despite advanced therapies in inflammatory bowel disease: a real-world patient-reported survey from Greece.Frontiers in immunology · 2026Article
- Patients' attitudes to disease prevention in inflammatory bowel disease: a US-based survey.Crohn's & colitis 360 · 2026Article
- Impact of Vedolizumab on Bowel Urgency in Ulcerative Colitis: Post Hoc Analysis of the GEMINI 1, VISIBLE 1, and VARSITY Trials.Gastro hep advances · 2026Article
- Unreliable information and fear: Barriers to vaccination among IBD patients in China.Human vaccines & immunotherapeutics · 2025Article
- Exploring the Mediating Role of Self-Efficacy in the Relationship Between Caregiver Contribution and Resilience in Inflammatory Bowel Disease.Behavioral sciences (Basel, Switzerland) · 2025Article
- Anti-tumor necrosis factor treatment from diagnosis is more effective and less costly than conventional "step-up" care for patients with active Crohn's disease: a cost-effectiveness analysis from the PROFILE trial.Journal of Crohn's & colitis · 2025Article
- Disease Burden and Unmet Medical Needs in Patients with Ulcerative Colitis in Greece: A Cross-Sectional Patient Survey.Medical sciences (Basel, Switzerland) · 2025Article
- Correlation of Income Instability With 12 Non-Communicable Disease Risks in Korea: A Prospective Cohort Study.Journal of Korean medical science · 2025Article
- Educational interventions to enhance support for balancing work and treatment in inflammatory bowel disease patients.Journal of gastroenterology · 2025Article
- Work Absenteeism in Inflammatory Bowel Disease Patients Related to Patient-Reported Anxiety Levels and Disease Activity: The IBD-GO-WORK Study.Journal of clinical medicine · 2025Article
- The extent to which family doctors have the ability to deal with patients with disabilities.Frontiers in medicine · 2025Article
- Regulation ofFrontiers in immunology · 2024Article
- Disease burden and unmet medical need in patients with Crohn's disease in Greece: a cross-sectional patient survey.Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
BACKGROUND AND
aimsThe impact of inflammatory bowel disease [IBD] on work productivity remains unclear. In this systematic review and meta-analysis, we quantify work-related outcomes and employment data among persons with IBD.
methodsA systematic literature search was conducted in MEDLINE, EMBASE, the Cochrane library, Scopus, ProQuest, and clinicaltrials.gov from inception to February 2023, to identify studies on work productivity in persons with IBD aged > 18 years. Work productivity was defined primarily by the Work Productivity and Activity Impairment [WPAI] questionnaire which includes absenteeism, presenteeism, overall work impairment, and non-work activity impairment. In addition, we included data on employment, sick leaves, disability pensions, and indirect costs due to productivity loss. Pooled effect analysis was conducted using a random-effects model for pooled estimates of continuous and proportional data with 95% confidence intervals.
resultsAmong all patients with IBD, the pooled estimates were 16.4% for absenteeism, 35.9% for presenteeism, 39.4% for overall work impairment, and 46.0% for non-work activity impairment. Indirect costs from overall work impairment were 5131.09 euros/patient/year. Only two-thirds of IBD patients were employed, and one in three lost their jobs due to IBD. Among those employed, 39.5% report sick days, 21.3% report work disability, and 12.3% receive disability pensions. Most studies demonstrate clinically meaningful improvements in work productivity with medical and/or surgical therapies.
conclusionPersons with IBD experience significant work impairment and associated indirect costs. This highlights the need for appropriate workplace accommodations and timely medical therapy to alleviate the burden of disease and improve work outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.